ArticleScientific reports2022
Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Drug Resistance in Multiple Myeloma: Tumor-Intrinsic Mechanisms and the Bone Marrow Microenvironment.Cell biochemistry and function · 2026Review
- When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era.Cancers · 2026Review
- A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.Cell reports. Medicine · 2026Article
- Review
- Targeting the immunological synapse in multiple myeloma.Discover oncology · 2026Review
- Liposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma.RSC advances · 2026Review
- Therapeutic options for extramedullary involvement in multiple myeloma.Clinical and experimental medicine · 2025Review
- Article
- Advanced quantification pipeline reveals new spatial and temporal tumor characteristics in preclinical multiple myeloma.EJNMMI research · 2025Article
- Evaluation of VLA-4 (Integrin α4β1) as a Shared Target for Radiopharmaceutical Therapy across Solid Tumors.Molecular cancer therapeutics · 2025Article
- ImmunoTar-integrative prioritization of cell surface targets for cancer immunotherapy.Bioinformatics (Oxford, England) · 2025Article
- IMMUNOTAR - Integrative prioritization of cell surface targets for cancer immunotherapy.bioRxiv : the preprint server for biology · 2024Article
- Article
- Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment.Cancers · 2024Review
- Current and Future PET Imaging for Multiple Myeloma.Life (Basel, Switzerland) · 2023Review
- Article
- Molecular imaging of bone metastasis.Journal of bone oncology · 2023Review
- First-in-Humans Evaluation of Safety and Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Molecular and immunological mechanisms of clonal evolution in multiple myeloma.Frontiers in immunology · 2023Review
- Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Multiple myeloma (MM) is a cancer of bone marrow (BM) plasma cells, which is increasingly treatable but still incurable. In 90% of MM patients, severe osteolysis results from pathological interactions between MM cells and the bone microenvironment. Delineating specific molecules and pathways for their role in cancer supportive interactions in the BM is vital for developing new therapies. Very Late Antigen 4 (VLA4, integrin α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.